Nuvelo's (NUVO) Jump May Be Attributed to Rumors for Further Trials on Alfimeprase

Nuvelo's (Nasdaq: NUVO) 47% jump may be attributed to an analyst saying there are rumors circulating that Bayer (NYSE: BAY) may decide to take NUVO's experimental blood clot dissolver for further trials, which have been temporarily suspended after failing to meet main goals - Reuters